1. |
Miyashita T, Akiyama K, Inamoto R, et al. Presence of FXYD6 in the endolymphatic sac epithelia. Neurosci Lett, 2012, 513(1):47-50.
|
2. |
窦春青, 岳鑫, 周宁新. hFXYD6反义核酸对胆管癌细胞体外增殖和侵袭能力的影响. 世界华人消化杂志, 2007, 15(10):929-935.
|
3. |
刘军桂, 周宁新, 张效东. FXYD6 shRNA表达载体的构建及其在体外对胰腺癌细胞增殖的影响. 生物技术通迅, 2009, 20(4):458-461.
|
4. |
Gao Q, Chen X, Duan H, et al. FXYD6:a novel therapeutic target toward hepatocellular carcinoma. Protein Cell, 2014, 5(7):532-543.
|
5. |
Li ZM, Zhang HY, Wang YX, et al. MicroRNA-137 is downregulated in human osteosarcoma and regulates cell proliferation and migra-tion through targeting FXYD6. J Drug Target, 2016, 24(2):102-110.
|
6. |
Hu HJ, Mao H, Shrestha A, et al. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma:A single-institution experi-ence in China. World J Gastroenterol, 2016, 22(8):2601-2610.
|
7. |
Loftas P, Arbman G, Sun XF, et al. FXYD3 expression in relation to local recurrence of rectal cancer. Radiat Oncol J, 2016, 34(1):52-58.
|
8. |
Ramírez-Backhaus M, Fernández-Serra A, Rubio-Briones J, et al. External validation of FXYD3 and KRT20 as predictive biomarkers for the presence of micrometastasis in muscle invasive bladder cancer lymph nodes. Actas Urol Esp, 2015, 39(8):473-481.
|
9. |
Li Y, Zhang X, Xu S,et al. Expression and clinical significance of FXYD3 in endometrial cancer. Oncol Lett, 2014, 8(2):517-522.
|
10. |
Raman P, Purwin T, Pestell R, et al. FXYD5 is a marker for poor prognosis and a potential driver for metastasis in ovarian carcinomas. Cancer Inform, 2015, 14:113-119.
|
11. |
Liu CC, Teh R, Mozar CA, et al. Silencing overexpression of FXYD3 protein in breast cancer cells amplifies effects of doxorubicin and γ-radiation on Na(+)/K (+)-ATPase and cell survival. Breast Cancer Res Treat, 2016, 155(2):203-213.
|
12. |
Giotakis I, Chrysovergis A, Georgolios A, et al. Adhesion molecules in cancer of the head and neck:role of dysadherin. J BUON, 2011, 16(4):609-612.
|
13. |
Kadowaki K, Sugimoto K, Yamaguchi F, et al. Phosphohippolin expression in the rat central nervous system. Brain Res Mol Brain Res, 2004, 125(1-2):105-112.
|
14. |
Biesemann C, Gronborg M, Luquet E, et al. Proteomic screening of glutamatergic mouse brain synaptosomes isolated by fluorescence activated sorting. EMBO J, 2014, 33(2):157-170.
|
15. |
Shiina N, Yamaguchi K, Tokunaga M. RNG105 deficiency impairs the dendritic localilocalization of mRNAs for Na+/K+ ATPase subunit isoforms and leads to the degeneration of neuronal networks. J Neurosci, 2010, 30(38):12816-12830.
|
16. |
肖梅, 周宁新, 高丽杰, 等. 半定量检测胆管癌组织中人fxyd6基因的表达. 中国普外基础与临床杂志, 2008, 15(2):83-87.
|
17. |
Liu J, Zhou N, Zhang X. A monoclonal antibody against human FXYD6. Hybridoma (Larchmt), 2011, 30(5):487-490.
|
18. |
李征, 何剪太. FXYD6蛋白在鼻咽癌组织中的表达. 中国耳鼻喉颅底外科杂志, 2011, 17(4):252-254, 258.
|
19. |
Murakami Y, Uemura K, Sudo T, et al. Perineural invasion in extra-hepatic cholangiocarcinoma:prognostic impact and treatment stra-tegies. J Gastrointest Surg, 2013, 17(8):1429-1439.
|
20. |
李成刚, 黄志强, 韦立新, 等. 肝门部胆管癌神经浸润及围肝门部神经丛的分布. 中华医学杂志, 2012, 92(38):2699-2702.
|
21. |
Bibert S, Liu CC, Figtree GA, et al. FXYD proteins reverse inhibition of the Na+-K+ pump mediated by glutathionylation of its beta1 subunit. J Biol Chem, 2011, 286(21):18562-18572.
|
22. |
Shindo Y, Morishita K, Kotake E, et al. FXYD6, a Na, K-ATPase regulator, is expressed in type Ⅱ taste cells. Biosci Biotechnol Biochem, 2011, 75(6):1061-1066.
|
23. |
Tummala R, Wolle D, Barwe SP, et al. Expression of Na, K-ATPase-beta(1) subunit increases uptake and sensitizes carcinoma cells to oxaliplatin. Cancer Chemother Pharmacol, 2009, 64(6):1187-1194.
|